Print this page    •   Back to Web version of article

The Body Covers: The 12th International AIDS Conference

Session 389/32406: Protease Inhibitors (PI) in the HIV+ Homeless and Marginally Housed (H/M): Good Adherence but Rarely Prescribed

Coverage provided by Michael Giordano, M.D.

July 1, 1998

Combination therapy with PIs is often withheld from poor or marginalized populations because of a biased assumption that adherence to therapy in this group of people will be poor. In addition to this assumption about the urban poor, there is the ethical quandary between a caregivers obligation to treat a patient, and a justified fear of inviting resistance via non-adherence.

This study looked at the prevalence of PI use (in combination with nukes), the level of viral suppression after use of PIs, subsequent resistance, and adherence to PI therapy. The study enrolled 153 economically disadvantaged HIV+ patients, recruited from San Francisco homeless shelters, free food lunch lines, and single room occupancy (SRO) hotels that cost under $400 a month. Bangsberg and colleagues measured baseline antiretroviral regimens, viral load after 1-3 months on therapy, proportion of patients who reached undetectable at 3-9 months, and any viral resistance.

Perhaps the most significant finding of this study is that after 20 months, the patients had attended 91% of all scheduled clinic visits. This contradicts the general bias -- held by many -- that poor people tend to be unreliable in keeping doctors' appointments.

PI use in the cohort rose dramatically over the study period. During July-September 1996, 3% of patients were on a protease-containing regimen; by January-March 1998 that number had risen to 26%. However, the total percentage of patients on any type of antiretroviral therapy never reached 50%.

Among patients on PIs, the mean viral load reduction after three months of therapy was 1.2 log. Only 30-40% of patients became undetectable in the 3-9 month follow-up period. This is generally a lower percentage than one would predict. This anomaly, according to the researchers, cannot be attributed solely to the emergence of viral resistance, since the resistance testing performed indicated that common mutations generally were not present in these patients.




This article was provided by TheBodyPRO.com. Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art14677.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.